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Abstract: Depressive disorders appear relatively frequently in older patients, and therefore represent
an important disease burden worldwide. Given the high levels of inflammatory parameters found in
depressed elderly patients, the “inflammaging” hypothesis is gaining strength. In this systematic review,
we summarize current evidence regarding the relationship between inflammatory parameters and
late-life depression, with a unique focus on longitudinal studies to guarantee temporality. According to
the data summarized in this review, the levels of some proinflammatory parameters—especially
interleukin (IL)-8, IL-6, and tumor necrosis factor (TNF)-α—could serve as biomarkers for the
future development of depressive symptoms in elderly patients. Proinflammatory cytokines seem
to be associated with the future development of clinically significant depression, irrespective of
baseline scores, thus indicating that inflammation temporally precedes and increases depression
risk. As insufficient research has been conducted in this field, further prospective studies are
clearly warranted.
Keywords: inflammation; aging; depression; late-life
1. Introduction
Life expectancy has continued to increase worldwide for several decades, especially in developed
countries, thus a proportional increase in diseases typically affecting older people is expected to be
observed in the coming years [1]. Depressive disorders—both major depressive disorder and, very often,
subthreshold depressive symptoms, either alone or in combination with other conditions—are among
the most common psychiatric disorders in the elderly, and they often do not respond as well to treatment
than those of younger ages. Despite extensive research aimed at improving our understanding of the
pathophysiology of these diseases, they still represent a significant cause of disease burden worldwide.
As such, more research is required, especially to elucidate the mechanisms triggering the disease,
in order to develop new preventive and treatment approaches.
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Three etiological hypotheses have been proposed for depressive disorders in the elderly [2]:
the “degenerative” hypothesis, according to which depression probably precedes the onset of
cognitive impairment and dementia [3]; the “vascular” hypothesis, due to the findings of white matter
lesions with neuroimaging studies in patients with late-life depression [4,5]; and the “inflammatory”
hypothesis, based on the high levels of inflammatory parameters found in depressed elderly patients [6],
which has led to the term “inflammaging” [7]. According to this latter hypothesis, aging shifts the
body into a proinflammatory state mediated by an increased immune response at the peripheral
level, impaired immune communication between the central nervous system and periphery, and an
increased and discordant central nervous system response [6]. All these changes lead to a chronic state
of neuroinflammation characterized by the continuous production of proinflammatory cytokines [8].
Indeed, the administration of cytokines has been shown to lead to depressive-like symptomatology [9,10]
that can be lessened by antidepressants [11], and antidepressant treatment decreases the stimulated
production of proinflammatory cytokines in depressed patients [12]. Moreover, as the degenerative,
vascular, and inflammatory hypotheses are not mutually exclusive [13], this overlap of models suggests
that inflammation can have a functional impact on brain structure [14].
Findings concerning inflammatory parameters and clinical correlates of depression have
been contradictory, this being attributed to differences in study designs, the inherent variability
in measurements of biological systems, and the different confounding factors considered in the
statistical analyses. While multiple studies have reported positive associations between inflammatory
mediators and late-life depression, some have not [15]. Most studies assessing the relationship between
inflammation and late-life depression are cross-sectional [16–21] or case-control studies [22,23], hence it
is unclear whether inflammatory conditions precede or follow the onset of symptoms.
The aim of the present review is to summarize the current evidence concerning the relationship
between inflammatory parameters and late-life depression by reviewing longitudinal studies of “good
methodological quality”; in other words, those articles that met minimum criteria of internal and
external validity, provided a good description of their objectives, had a design in accordance with
these objectives, a sufficiently large sample size, and presented their results clearly.
2. Literature Search
Publications were identified by way of a systematic literature search conducted initially in
September 2014, which was repeated in May 2015; the review is reported in accordance with the PRISMA
(Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement [24]. The search was
conducted for papers published between January 2000 and May 2015 using the PubMed, Embase,
PsychINFO, Trip, and Web of Science databases, and the electronic database searches were supplemented
by cross-referencing of selected articles and a manual search.
The search terms “inflammation”, “depression”, “aged”, “aging”, and “elderly” were used to
search for publications reporting prospective studies assessing inflammatory parameters in cohorts of
elderly subjects (≥60 years old), exploring their relationship with major depressive disorder and not
with other conditions. Publications in English, French, or Spanish were included. Studies reporting only
cross-sectional data and genetic studies were excluded. The purpose of including only longitudinal
studies was to explore temporality, which provides greater consistency to a causal model.
Selected publications were assessed by two independent raters using a critical appraisal tool
platform [25]. This tool allows an in-depth analysis of all the key points that determine a study’s
methodological quality by evaluating different aspects of the quality of the article (internal and external
validity, clear objectives, sample size, presentation of results, etc.), and thereby classifies studies as
having high, medium, or low methodological quality. Only papers classified as being of high or
medium quality were included in this review. The tool also helps the reader to summarize the main
characteristics of a paper.
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3. Results
The initial literature search identified 217 publications potentially eligible for inclusion, of which 23
were selected after analyzing each of the abstracts. After excluding 8 of these for being duplicates,
and including a further 3 from the manual search, we obtained a sample of 18 papers for which we
proceeded to carefully read the full text. Eleven of these papers were excluded because they had
a cross-sectional or case-control design, and 1 was excluded due to its low methodological quality.
Finally, we selected 6 manuscripts, which were examined in depth, for inclusion in our systematic
review (Figure 1).
Int. J. Mol. Sci. 2016, 17, 2022 3 of 12 
3. Results 
The initial literature search identified 217 publications potentially eligible for inclusion, of 
which 23 were selected after analyzing each of the abstracts. After excluding 8 of these for being 
duplicates, and including a further 3 from the manual search, we obtained a sample of 18 papers for 
which we proceeded to carefully read the full text. Eleven of these papers were excluded because 
they had a cross-sectional or case-control design, and 1 was excluded due to its low methodological 
quality. Finally, we selected 6 manuscripts, which were examined in depth, for inclusion in our 
systematic review (Figure 1). 
 
Figure 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart 
of publications selection procedure. 
Only six studies met the selection criteria and had prospectively evaluated the relationship 
between peripheral inflammatory biomarkers and depression in older people. Samples varied in size 
from 263 to 1037 participants and the mean age range varied from 61 to 85 years. All but one of the 
studies evaluated the influence of biological measures on depressive symptoms [26–30], while the 
other study evaluated the relation between these variables in both directions [31]. Five of the studies 
were conducted in Europe, one in Australia, and one in the USA. The main characteristics of these 
studies are listed in Table 1. 
. i i i l fl
f li ti l ti .
Only six studies met the selection criteria and had prospectively evaluated the relationship
between peripheral inflammatory biomarkers and depression in older people. Samples varied in size
from 263 to 1037 participants and the mean age range varied from 61 to 85 years. All but one of the
studies evaluated the influence of biological measures on depressive symptoms [26–30], while the
other study evaluated the relation between these variables in both directions [31]. Five of the studies
were conducted in Europe, one in Australia, and one in the USA. The main characteristics of these
studies are listed in Table 1.
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Table 1. Main characteristics of cohort studies included in the review.
Study Country Follow-Up Sample Age Mean (SD)
Inflammatory
Parameters
Assessed *
Directionality
of the Explored
Relationship
Measure of
Depression ** Change Score Confounders Considered Results Potential Bias
Baune,
2012 [26] Australia 2 years
1037
non-depressed
and non-
demented individuals
78.8 (4.8)
IL-1β, IL-6, IL-8,
IL-10, IL-12p70
CRP, PAI-1,
sVCAM-1,
SAA, TNF-α
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Study Country Follow-Up Sample 
Age
Mean 
(SD) 
Inflammatory 
Parameters 
Assessed * 
Directionality of 
the Explored 
Relationship 
Measure of 
Depression ** 
Change 
Score 
Confounders 
Considered Results Potential Bias 
Baune,  
2012 [26] 
Australia 2 years 
1037 
non-depressed 
and 
non-demented 
individuals 
78.8 
(4.8) 
IL-1β, IL-6, 
IL-8, IL-10, 
IL-12p70  
CRP, PAI-1, 
sVCAM-1, 
SAA, TNF-α 
 GDS [32] 
• Cutoff of  
≥6 for 
depression 
• Gender, age, years of 
education, total 
number of medical 
disorders, 
cardiovascular 
disorders, endocrine 
disorders, smoking, 
BMI, current 
antidepressants, 
NSAIDs, statins, Mini 
Mental State 
Examination and 
Diabetes Mellitus 
• IL-8 and IL-6 at 
baseline were directly 
related to depression 
severity at baseline 
• IL-8 at baseline 
directly predicted 
depressive symptoms 
at follow-up 
• IL-12p70 at baseline 
showed an inverse 
relationship with GDS 
score at follow-up 
• Remitted depression 
at baseline was 
associated with 
baseline PAI-1 levels 
• A structured 
interview was not 
used to 
determine the 
diagnosis of 
depression 
Bremmer, 
2008 [27] 
The 
Netherlands 
1 year 
1285 elderly 
people 
75.4 
(6.6) 
Il-6, CRP  
CES-D [33] and 
NIMH-Diagnostic 
Interview 
Schedule [34] 
• Cutoff of 
≥16 for 
depression 
• Age, gender, 
educational level, 
household 
composition, current 
smoking, alcohol 
intake, medication 
use, several 
cardiovascular risk 
factors and chronic 
diseases 
• IL-6 plasma levels, but 
not CRP, were 
independently 
associated with major 
depression (either first 
or recurrent episodes). 
OR = 3.18 for 
depression in patients 
with high IL-6 levels 
• No association 
between inflammatory 
parameters with 
respect to symptom 
profiles 
 
Forti,  
2010 [28] 
Italy 4 years 
704 elderly 
people 
73.4 
(6.1) 
IL-6, CRP, 
ICAM-1, ACT, 
TNF-α 
 GDS, DSM-IV 
criteria 
• Cutoff of 
≥10 for 
depression 
• Years of education, 
BMI, cardiovascular 
disease, comorbidity, 
physical disability, 
anti-inflammatory 
drug use 
• U-shaped association 
between TNF-α and 
risk of incident 
depressive symptoms 
• A structured 
interview was not 
used to 
determine the 
diagnosis of 
depression 
GDS [32]
• Cutoff of ≥6
for depression
• Gender, age, years
of education, total
number of medical
disorders,
cardiovascular
isorders, end crine
disorders, smoking,
BMI, current
antidepressants,
NSAIDs, statins,
Mini Mental State
Exami ation and
Diabetes Mellitus
• IL-8 and IL-6 at
baseline were directly
related to depression
severity at baseline
• IL-8 at baseline
directly predicted
depressive symptoms
at follow-up
• IL-12p70 at baseline
showed an inverse
relationship with
GDS score
at follow-up
• Remitted depression
at baseline was
associated with
baseline PAI-1 levels
• A structured
interview was
not used to
determine the
diagnosis
of depression
Bremmer,
2008 [27] The Netherlands 1 year
1285
elderly people 75.4 (6.6) Il-6, CRP
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Study Country Follow-Up Sample 
Age
Mean 
(SD) 
Inflammatory 
Parameters 
Assessed * 
Directionality of 
the Explored 
Relationship 
Measure of 
Depression ** 
Change 
Score 
Confounders 
Considered Resul s Potential Bias 
Baune,  
2012 [26] 
Australia 2 years 
1037 
non-depressed 
and 
non-demented 
individuals 
78.8 
(4.8) 
IL-1β, IL-6, 
IL-8, IL-10, 
IL-12p70  
CRP, PAI-1, 
sVCAM-1, 
SAA, TNF-α 
 GDS [32] 
• Cutoff of  
≥6 for 
depression 
• Gender, age, years of 
education, total 
number of medical 
disorders, 
cardiovascular 
disorders, endocrine 
disorders, smoking, 
BMI, current 
antidepressants, 
NSAIDs, statins, Mini 
Mental State 
Examination and 
Diabetes Mellitus 
• IL-8 and IL-6 at 
baseline were directly 
relat d t  depression 
severity at baselin  
 IL-8 at baseline 
directly predicted 
depressive symptoms 
at follow-up 
• IL-12p70 at baseline 
showed an inverse 
relationship with GDS 
score at follow-up 
• Remitted depression 
at baselin  was 
associated with 
baseline PAI-1 levels 
• A structured 
interview was not 
used to 
determine the 
diagnosis of 
depression 
Bremmer, 
2008 [27] 
The 
Netherlands 
1 year 
1285 elderly 
people 
75.4 
(6.6) 
Il-6, CRP  
CES-D [33] and 
NIMH-Diagnostic 
Interview 
Schedule [34] 
• Cutoff of 
≥16 for 
depression 
• Age, gender, 
educational level, 
household 
composition, current 
smoking, alcohol 
intake, medication 
use, several 
cardiovascular risk 
factors and chronic 
diseases 
• IL-6 plasma levels, but 
not CRP, were 
independently 
associated with major 
depression (either first 
or recurrent episodes). 
OR = 3.18 for 
depression in patients 
with high IL-6 levels 
• No association 
between inflammatory 
parameters with 
respect to symptom 
profiles 
 
Forti,  
2010 [28] 
Italy 4 years 
704 elderly 
people 
73.4 
(6.1) 
IL-6, CRP, 
ICAM-1, ACT, 
TNF-α 
 GDS, DSM-IV 
criteria 
• Cutoff of 
≥10 for 
depression 
• Years of education, 
BMI, cardiovascular 
disease, comorbidity, 
physical disability, 
anti-inflammatory 
drug use 
• U-shaped association 
between TNF-α and 
risk of incident 
depressive symptoms 
• A structured 
interview was not 
used to 
determine the 
diagnosis of 
depression 
CES-D [33] and
NIMH-Diagnostic
Interview
Schedule [34]
• Cutoff of ≥16
for depression
• Age, gender,
educational level,
household
composition,
cur nt smoking,
alcohol intake,
medication use,
several
cardiovascular risk
fact rs and
chronic diseases
• IL-6 plasma levels,
but not CRP, were
independently
associated with major
depression (either
first or recurrent
episodes). OR = 3.18
for depression in
patients with high
IL-6 levels
• No association
between inflammatory
parameters with
respect to
symptom profiles
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Table 1. Cont.
Study Country Follow-Up Sample Age Mean (SD)
Inflammatory
Parameters
Assessed *
Directionality
of the Explored
Relationship
Measure of
Depression ** Change Score Confounders Considered Results Potential Bias
Forti,
2010 [28] Italy 4 years 704 elderly people 73.4 (6.1)
IL-6, CRP, ICAM-1,
ACT, TNF-α
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1037 
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and 
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Mental State 
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• IL-8 and IL-6 at 
baseline were directly 
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directly predicted 
depressive symptoms 
at follow-up 
• IL-12p70 at baseline 
showed an inverse 
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score at follow-up 
• Remitted depression 
at baseline was 
associated with 
baseline PAI-1 levels 
• A structured 
interview was not 
used to 
determine the 
diagnosis of 
depression 
Bremmer, 
2008 [27] 
The 
Netherlands 
1 year 
1285 elderly 
people 
75.4 
(6.6) 
Il-6, CRP  
CES-D [33] and 
NIMH-Diagnostic 
Interview 
Schedule [34] 
• Cutoff of 
≥16 for 
depression 
• Age, gender, 
educational level, 
household 
composition, current 
smoking, alcohol 
intake, medication 
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cardiovascular risk 
factors and chronic 
diseases 
• IL-6 plasma levels, but 
not CRP, were 
independently 
associated with major 
depression (either first 
or recurrent episodes). 
OR = 3.18 for 
depression in patients 
with high IL-6 levels 
• No association 
between inflammatory 
parameters with 
respect to symptom 
profiles 
 
Forti,  
2010 [28] 
Italy 4 years 
704 elderly 
people 
73.4 
(6.1) 
IL-6, CRP, 
ICAM-1, ACT, 
TNF-α 
 GDS, DSM-IV 
criteria 
• Cutoff of 
≥10 for 
depression 
• Years of education, 
BMI, cardiovascular 
disease, comorbidity, 
physical disability, 
anti-inflammatory 
drug use 
• U-shaped association 
between TNF-α and 
risk of incident 
depressive symptoms 
• A structured 
interview was not 
used to 
determine the 
diagnosis of 
depression 
GDS,
DSM-IV criteria
• Cutoff of ≥10
for depression
• Years of education,
BMI, cardiovascular
disease, comorbidity,
physical disability,
anti-inflammatory
drug use
• U-shaped association
between TNF-α and
risk of incident
depressive symptoms
• A structured
interview was
not used to
determine the
diagnosis
of depression
Milaneschi,
2009 [29] Italy 3 and 6 years 778 elderly people 75 (7)
IL-6, sIL-6r, IL-1β,
IL-1ra, TNF-α,
IL-18, CRP
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Change 
Score 
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Considered Results Potential Bias 
Baune,  
2012 [26] 
Australia 2 years 
1037 
non-depressed 
and 
non-demented 
individuals 
78.8 
(4.8) 
IL-1β, IL-6, 
IL-8, IL-10, 
IL-12p70  
CRP, PAI-1, 
sVCAM-1, 
SAA, TNF-α 
 GDS [32] 
• Cutoff of  
≥6 for 
depression 
• Gender, age, years of 
education, total 
number of medical 
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cardiovascular 
disorders, endocrine 
disorders, smoking, 
BMI, current 
antidepressants, 
NSAIDs, statins, Mini 
Mental State 
Examination and 
Diabetes Mellitus 
• IL-8 and IL-6 at 
baseline were directly 
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depressive symptoms 
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showed an inverse 
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score at follow-up 
• Remitted depression 
at baseline was 
associated with 
baseline PAI-1 levels 
• A structured 
interview was not 
used to 
determine the 
diagnosis of 
depression 
Bremmer, 
2008 [27] 
The 
Netherlands 
1 year 
1285 elderly 
people 
75.4 
(6.6) 
Il-6, CRP  
CES-D [33] and 
NIMH-Diagnostic 
Interview 
Schedule [34] 
• Cutoff of 
≥16 for 
depression 
• Age, gender, 
educational level, 
household 
composition, current 
smoking, alcohol 
intake, medication 
use, several 
cardiovascular risk 
factors and chronic 
diseases 
• IL-6 plasma levels, but 
not CRP, were 
independently 
associated with major 
depression (either first 
or recurrent episodes). 
OR = 3.18 for 
depression in patients 
with high IL-6 levels 
• No association 
between inflammatory 
parameters with 
respect to symptom 
profiles 
 
Forti,  
2010 [28] 
Italy 4 years 
704 elderly 
people 
73.4 
(6.1) 
IL-6, CRP, 
ICAM-1, ACT, 
TNF-α 
 GDS, DSM-IV 
criteria 
• Cutoff of 
≥10 for 
depression 
• Years of education, 
BMI, cardiovascular 
disease, comorbidity, 
physical disability, 
anti-inflammatory 
drug use 
• U-shaped association 
between TNF-α and 
risk of incident 
depressive symptoms 
• A structured 
interview was not 
used to 
determine the 
diagnosis of 
depression 
CES-D
• Cutoff of ≥20
for depression
• Age, gender, site,
ye rs of education,
smoking habit,
alcohol use, Mini
Mental Stare
Examination Score,
BMI, number of
drugs, use of
NSAIDs,
c diovascular
diseases and
physical activity
• IL-1ra predicted the
development of
depre sed mood
over 6 years’
follow-up; effect not
detectable at the
3-year assessment
• A structured
interview was
not used to
determine the
diagnosis
of depression
• The study
design did
not allow
depressive
episodes
started and
remitted
between
follow-up
visits to
be detected
Stewart,
2009 [31] USA 6 years
263 healthy adults
(50–70 years) 61 (4.8) IL-6, CRP
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Milaneschi, 
2009 [29] 
Italy 
3 and  
6 years 
778 elderly 
people 
75 (7) 
IL-6, sIL-6r, 
IL-1β, IL-1ra, 
TNF-α, IL-18, 
CRP 
 CES-D 
• Cutoff of 
≥20 for 
depression 
• Age, gender, site, 
years of education, 
smoki g habit, 
alcohol use, Mini 
Mental Stare 
Examinati n Score, 
BMI, number of 
drugs, use of 
NSAIDs, 
cardiovascular 
diseases and physical 
activity 
• IL-1ra predicted the 
development of 
depresse  mood over 
6 years’ follow-up; 
effect not detectable at 
the 3-year assessment 
• A structured 
interview was not 
used to 
determine the 
diagnosis of 
depression 
• Th  study design 
did not allow 
pressive 
episodes started 
and remitted 
between 
follow-up visits 
to be detected 
Stewart, 
2009 [31] USA 6 years 
263 healthy 
adults  
(50–70 years) 
61 
(4.8) IL-6, CRP 
 BDI-II [35] 
• Change in 
the BDI-II 
score 
• Blood pressure, BMI, 
HDL cholesterol, 
triglycerides, fasting 
glucose, fasting 
insulin, diabetes, 
rheumatoid arthritis, 
carotid intima-media 
thickness, smoking 
status, alcohol intake 
and physical activity 
• Neither baseline IL-6 
nor CRP were 
predictors of BDI-II 
change during the 
follow-up 
• Baseline BDI-II was 
positively associated 
with IL-6 change but 
was not a predictor of 
CRP change 
• Results not 
generalizable to 
racial groups 
other than white 
people, because 
only 35 
non-white people 
were included in 
th  study 
Van den 
Biggelaar, 
2007 [30] 
The 
Netherlands 5 years 599 aged people 85 (0) 
IL-1β, IL-1ra, 
IL-6, IL-10, 
CPR, TNF-α 
 GDS 
• Cutoff of  
≥5 for 
depression 
• Gender, educ tion, 
Mini M ntal State 
Examination Score, 
comorbidity, 
disability, current 
smoking, BMI, serum 
levels of albumin, 
CRP and 
LPS-induced cytokine 
• Increased levels of 
IL-1β and CPR were 
significantly related to 
an increase in 
depressive symptoms 
• Increased levels of 
IL-1ra were related to 
a decrease in the risk 
of developing 
depression 
• A structured 
interview was not 
used to 
determine the 
diagnosis of 
depression 
* IL: Interleukin; CRP: C-reactive protein; PAI-1: plasminogen activator inhibitor-1; sVCAM-1: serum vascular cell adhesion molecule-1; SAA: serum amyloid A; 
TNF-α: tumor necrosis factor-α; sIL-6r: soluble IL-6 receptor; IL-1ra: IL-1 receptor antagonist; ICAM-1: intracellular adhesion molecule-1; ACT: 
α-1-antichymotrypsin; ** GDS: Geriatric Depression Scale [32]; CES-D: Center for Epidemiological Studies-Depression Scale [33]; BDI-II: Beck Depression 
Inventory-II [35]. 
BDI-II [35]
• Change in the
BDI-II score
• Blood pressure,
BMI, HDL
cholesterol,
triglycerides,
fasting glucose,
fasting i sulin,
diabetes,
rheumatoid
arthritis, caroti
in ima-media
thickness, smoking
status, alcohol
intake and
physical activity
• N i her baseline IL-6
nor CRP were
predictors of BDI-II
change during
e follow-up
• Baseline BDI-II was
positively associated
with IL-6 change but
was not a predictor of
CRP change
• Results not
generalizable
to racial
groups other
than white
people,
because only
35 non-white
people were
included in
the study
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Table 1. Cont.
Study Country Follow-Up Sample AgeMean (SD)
Inflammatory
Parameters
Assessed *
Directionality
of the Explored
Relationship
Measure of
Depression ** Change Score Confounders Considered Results Potential Bias
Van den
Biggelaar,
2007 [30]
The Netherlands 5 years 599 aged people 85 (0)
IL-1β, IL-1ra,
IL-6, IL-10, CPR,
TNF-α
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Table 1. Main characteristics of cohort studies included in the review. 
Study Country Follow-Up Sample 
Age
Mean 
(SD) 
Inflammatory 
Parameters 
Assessed * 
Directionality of 
the Explored 
Relationship 
Measure of 
Depression ** 
Change 
Score 
Confounders 
Considered Results Potential Bias 
Baune,  
2012 [26] 
Australia 2 years 
1037 
non-depressed 
and 
non-demented 
individuals 
78.8 
(4.8) 
IL-1β, IL-6, 
IL-8, IL-10, 
IL-12p70  
CRP, PAI-1, 
sVCAM-1, 
SAA, TNF-α 
 GDS [32] 
• Cutoff of  
≥6 for 
depression 
• Gender, age, years of 
education, total 
number of medical 
disorders, 
cardiovascular 
disorders, endocrine 
disorders, smoking, 
BMI, current 
antidepressants, 
NSAIDs, statins, Mini 
Mental State 
Examination and 
Diabetes Mellitus 
• IL-8 and IL-6 at 
baseline were directly 
related to depression 
severity at baseline 
• IL-8 at baseline 
directly predicted 
depressive symptoms 
at follow-up 
• IL-12p70 at baseline 
showed an inverse 
relationship with GDS 
score at follow-up 
• Remitted depression 
at baseline was 
associated with 
baseline PAI-1 levels 
• A structured 
interview was not 
used to 
determine the 
diagnosis of 
depression 
Bremmer, 
2008 [27] 
The 
Netherlands 
1 year 
1285 elderly 
people 
75.4 
(6.6) 
Il-6, CRP  
CES-D [33] and 
NIMH-Diagnostic 
Interview 
Schedule [34] 
• Cutoff of 
≥16 for 
depression 
• Age, gender, 
educational level, 
household 
composition, current 
smoking, alcohol 
intake, medication 
use, several 
cardiovascular risk 
factors and chronic 
diseases 
• IL-6 plasma levels, but 
not CRP, were 
independently 
associated with major 
depression (either first 
or recurrent episodes). 
OR = 3.18 for 
depression in patients 
with high IL-6 levels 
• No association 
between inflammatory 
parameters with 
respect to symptom 
profiles 
 
Forti,  
2010 [28] 
Italy 4 years 
704 elderly 
people 
73.4 
(6.1) 
IL-6, CRP, 
ICAM-1, ACT, 
TNF-α 
 GDS, DSM-IV 
criteria 
• Cutoff of 
≥10 for 
depression 
• Years of education, 
BMI, cardiovascular 
disease, comorbidity, 
physical disability, 
anti-inflammatory 
drug use 
• U-shaped association 
between TNF-α and 
risk of incident 
depressive symptoms 
• A structured 
interview was not 
used to 
determine the 
diagnosis of 
depression 
GDS
• Cutoff of ≥5
for depression
• Gender, education,
Mini Mental State
Examination Scor ,
comorbidity,
disability, current
smoking, BMI, serum
levels of albumin,
CRP and LPS-
induced cytokine
• Increased levels of
IL-1β and CPR were
significantly related
to an increase in
depressive symptoms
• Increased levels of
IL-1ra were related
to a decrease
in the risk of
developing depression
• A structured
interview was
not used to
determine
the diagnosis
of depression
* IL: Interleukin; CRP: C-reactive protein; PAI-1: plasminogen activator inhibitor-1; sVCAM-1: serum vascular cell adhesion molecule-1; SAA: serum amyloid A; TNF-α: tumor necrosis
factor-α; sIL-6r: soluble IL-6 receptor; IL-1ra: IL-1 receptor antagonist; ICAM-1: intracellular adhesion molecule-1; ACT: α-1-antichymotrypsin; ** GDS: Geriatric Depression Scale [32];
CES-D: Center for Epidemiological Studies-Depression Scale [33]; BDI-II: Beck Depression Inventory-II [35].
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The immunological markers examined in the articles reviewed are listed in Table 2.
Table 2. Immunological markers and their role in inflammatory processes assessed in the articles reviewed.
Proinflammatory parameters
IL-1β: Interleukin 1β
IL-6: Interleukin 6
sIL-6r: soluble IL-6 receptor
IL-8: Interleukin 8
IL-12p70: IL-12 heterodimer
IL-18: Interleukin 18
CRP: C-reactive protein
TNF-α: Tumor necrosis factor α
ICAM-1: Intercellular adhesion molecule 1
ACT: α 1-antichymotrypsin
PAI-1: Plasminogen activator inhibitor-1
sVCAM-1: Soluble vascular cell adhesion molecule 1
Anti-inflammatory parameters IL-1ra: IL-1 receptor antagonist
IL-10: Interleukin 10
Baune et al. [26] followed up on a cohort of 1037 Australian non-demented elderly patients for
two years. Of these, 71 patients already had mild to moderate depressive symptoms at the baseline
assessment, and 42 developed such symptoms during follow-up. The peripheral parameters assessed
were levels of interleukin 1β (IL-1β), IL-6, IL-8, IL-10, IL-12p70, C-reactive protein (CRP), plasminogen
activator inhibitor-1 (PAI-1), vascular adhesion molecule-1 (sVCAM-1), serum amyloid-A (SAA),
and tumor necrosis factor-α (TNF-α). At baseline, elevated levels of IL-8 and IL-6 were related
to higher levels of depressive symptoms, as assessed using the Geriatric Depression Scale (GDS)
(odds ratio (OR) = 1.042; p = 0.025 and OR = 1.041; p = 0.035, respectively). Interestingly, elevated levels
of IL-8 at baseline predicted significantly higher GDS scores at follow-up (OR = 1.043; p = 0.038) and
were also associated with the first onset of mild to moderate depressive symptoms over two years
(OR = 1.052; p = 0.038). Moreover, IL-12p70 showed a significant inverse relationship with GDS scores
(OR = 0.992; p = 0.010).
In their population-based study, Bremmer et al. [27] included 1285 participants aged 65 and over
living in the Netherlands and followed them up for one year. The authors assessed IL-6 and CRP at
baseline and depressive symptoms using the Center for Epidemiological Studies—Depression (CES-D)
scale. Patients with depression scores ≥ 16 were thoroughly assessed according to Diagnostic and
Statistical Manual of Mental Disorders (DSM)-III criteria [35] for a diagnosis of major depressive
disorder. Although no significant associations were found with CRP levels, high levels of IL-6
(above 5 pg/mL) were associated with major depression during the follow-up (OR = 2.49 (1.07–5.80))
both in first and recurrent episodes (OR = 2.87 (0.75–10.9) and OR = 2.17 (0.86–5.49), respectively).
Furthermore, the authors found an OR of 3.18 for depression in patients with high IL-6 levels.
With regard to symptom profile, they found no association with inflammatory parameters.
Forti et al. conducted an interesting study in Italy following up a sample of 704 elderly individuals
for four years and assessed the incidence of depressive symptoms using the GDS [28]. Only TNF-α
levels showed an association with incident depression, with this association having a U-shaped form.
Subjects with detectable TNF levels of up to 10 pg/mL were at a lower risk of developing depressive
symptoms than subjects with undetectable TNF levels (p = 0.015). No association was found for TNF
values higher than 10 pg/mL (p > 0.05).
Similarly, Milaneschi et al. conducted a follow-up study of a sample of 778 elderly patients,
with two follow-up assessments (three and six years after evaluating their baseline levels) of several
inflammatory parameters [29]. These authors investigated the presence of depressive symptomatology
using the Center for Epidemiological Studies—Depression scale at both follow-up assessments,
and concluded that the IL-1 receptor antagonist (IL-1ra) predicted the development of depressed mood
in the long term, this association being detectable at six years but not earlier (i.e., three-year assessment).
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In contrast, and with regard to IL-1ra, van den Biggelaar et al. found that higher baseline levels of
this soluble receptor were related to a lower risk of developing depression, as evaluated in a five-year
follow-up assessment [30]. These authors also reported a significant relationship between IL-1β and
CRP levels at baseline and increases in depressive mood, as measured using the GDS scale.
The aim of all the studies discussed thus far was to evaluate the influence of various inflammatory
variables on the development of depressed mood over a given follow-up period. In contrast, the study
published by Stewart et al. in 2009 followed a bidirectional approach; in other words, these authors
also explored the association of baseline depressive symptoms with IL-6 and CRP levels over a six-year
period [31]. They found that neither baseline IL-6 nor CRP levels behaved as predictors of the change
in Beck Depression Inventory-II (BDI-II) scores during follow-up. Interestingly, the baseline Beck
Depression Inventory-II scores correlated positively with changes in IL-6 levels over the follow-up
period, but not with changes in CRP levels.
4. Discussion
According to the data summarized in this review, the levels of some proinflammatory parameters—
namely IL-8, IL-6, and TNF-α—could serve as biomarkers for the future onset of depressive symptoms
in elderly patients. Having said that, their prognostic value should be explored further given that,
for example, Stewart et al. [31] did not replicate the previous findings of Bremmer [27] concerning
IL-6. Such inconsistencies could be due to age differences between samples (61 vs. 75.4 years) and to
the different tools used to assess depressive symptomatology (BDI-II vs. CES-D). The discrepancies
found support the need for further studies using similar samples and designs that replicate and
confirm the results of previous studies. The relevance of TNF-α is supported by the recent review of
Bortolato et al., who indicate that TNF-α antagonists play an important role in mitigating depressive
symptoms and improving cognitive deficits in elderly patients [36]. There is also evidence that IL-6
and TNF-α could act as mediators in the incidence of depressive symptoms in patients with some
other diseases, such as coronary artery disease [37] or multiple sclerosis [38]. TNF-α may contribute to
the pathophysiology of depression by activating the hypothalamic–pituitary–adrenal (HPA) axis and
neuronal serotonin transporters and by stimulating the enzyme indoleamine-2,3-dioxygenase (IDO),
which causes tryptophan depletion [39].
With respect to IL-8, there is some evidence that this interleukin is related to depressive symptoms
both at baseline and two years later, although, to the best of our knowledge, only one trial [26]
has assessed it and the ORs reported were not very conclusive (OR = 1.36 (95% CI = 1.021–1.802,
p = 0.035) and 0.94 (95% CI = 0.67–1.32, p = 0.719), respectively). In line with this, a prospective study
reported that the associations between the onset of depression and physical comorbidities in elderly
subjects were significant in the presence of higher IL-8 production [40]. In addition, one postmortem
study found that IL-8 expression was upregulated in Brodmann area 10 (prefrontal cortex) of brains
from psychotropic drug-free individuals with a history of major depressive disorder compared to its
expression in matched controls [41]. On the other hand, a recent systematic review concluded that the
findings from cross-sectional studies regarding the relationship between depression and serum IL-8
levels in nongeriatric populations remained unclear [42], although a study conducted in 2003 found
that IL-8 levels significantly and positively correlated with current depressive symptoms in a sample
of 53 young men [43]. Considering these previous studies together, we conclude that further research
is needed to elucidate the relationship between IL-8 and the development of depressive symptoms in
elderly subjects.
With regard to IL-6, this interleukin showed a stronger association with the development of
depressive symptomatology after one year (OR = 3.18), although no distinction was made between the
different endophenotypes of the disease [27]. Similarly, a prospective population-based study found
higher IL-6 and IL-8 levels in the cerebrospinal fluid (CSF) of elderly depressed women, this fluid being
a better tissue for representing the central nervous system than peripheral blood due to its proximity
to said system [44]. These results may be supported by previous meta-analyses [42–44].
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Dowlati et al. observed significantly higher concentrations of IL-6 in depressed individuals than
in healthy controls. In addition, Endrighi et al. showed an association between negative mood and
stress-induced IL-6 responses in healthy young individuals [45]. IL-6 strongly activates the HPA axis
and, therefore, may also contribute to the hypercortisolism observed in depression [46]. In regard to
the type of depressive symptoms, Capuron et al. only observed that IL-6 appeared to be related to the
“reduced appetite” score of the Montgomery–Asberg Depression Rating Scale in elderly subjects [47].
Moreover, a recently published review concluded that IL-6 is the cytokine most robustly associated
with suicidal ideation, suicides, and nonfatal suicide attempts [48], thereby suggesting an important
role of this interleukin in this aspect of depression. The authors found that the results for other
inflammatory parameters were inconclusive.
With regard to TNF-α, the level of this protein appeared to have a U-shaped association with
risk of incident depressive symptoms in elderly individuals [28]. In line with this, a prospective
study found that the relationships between the onset of depression and physical disorders in elderly
people were significant in the presence of higher TNF-α production, similar to production of IL-8,
as cited previously [40]. Additionally, the findings from previous meta-analyses indicate that depressed
individuals have significantly higher TNF-α and IL-6 concentrations than controls [49,50].
IL-1ra should be investigated more exhaustively, given the inconsistent results found in our
systematic review. Thus, Milaneschi et al. [29] reported that IL-1ra predicted the development of
depressed mood over a six-year follow-up period, whereas van den Biggelaar et al. [30] found
that increased IL-1ra levels were related to a lower risk of developing depression. These divergent
findings may be due to differences in the methodology and study samples; in particular, the disparity
between direct in vivo serum measurements [29] and ex vivo whole sample blood lipopolysaccharide
stimulation [30], and the gap in mean ages between the trials [51]. A systematic review concluded
that IL-1ra concentrations were frequently upregulated in depressed patients [52]. In line with this
review, previous studies have found higher levels of serum IL-1ra in depressed patients than in healthy
populations [44,49,50,53].
Additionally, in population-based research in middle-aged individuals, higher IL-1ra levels have
been associated with elevated depressive symptoms [51,54]. Similarly, a cohort study of healthy
middle-aged men found evidence that higher IL-1ra levels may be associated with depression and
increased mortality [55]. Furthermore, at the preclinical level, research conducted in IL-1ra knockout
mice, which display an aging-induced anxiety-like phenotype, suggests an interaction between this
receptor and aging in the development of depressive symptoms [56]. Taking these findings as a whole,
we conclude that further research is also required to explore the association between IL-1ra and the
development of depressive symptomatology in elderly people.
As mentioned above, one plausible explanation for why all these inflammatory variables influence
the development of depressive symptoms is that the enzyme indoleamine-2,3-dioxygenase (IDO) is
induced upon immune activation. When induced, this enzyme catalyzes the conversion of tryptophan
into kynurenine, thus causing depletion of the tryptophan available to synthesize serotonin [39,57].
Furthermore, alterations in serotonergic, noradrenergic, and glutamatergic neurotransmission have also
been related to low-level neuroinflammation and may be involved in the development of depressive
symptoms [58].
It should be noted here that most of the articles reviewed were able to show that proinflammatory
cytokines are associated with the future development of clinically significant depression, independent
of baseline scores, thus indicating that inflammation temporally precedes and increases depression
risk, although very few studies have addressed this subject to date.
The methodology, follow-up period, set of pro-/anti-inflammatory parameters evaluated, and tool
used to assess depressive symptoms vary considerably between the studies included in this systematic
review. As such, there is a clear need to conduct further research into this issue with uniform criteria
across studies, including the inflammatory parameters highlighted in this review and a common
clinical scale to measure depressive symptoms. There is also a need to study inflammatory markers in
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CSF and—as central inflammation can be assessed using positron emission tomography (PET) ligands
specific for the translocator protein (TPSO)—to undertake in vivo PET studies both during depression
and after recovery.
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